TGF-alpha as a candidate tumor antigen for renal cell carcinomas
Identifieur interne : 002A52 ( Main/Exploration ); précédent : 002A51; suivant : 002A53TGF-alpha as a candidate tumor antigen for renal cell carcinomas
Auteurs : Sandy Pelletier [Canada] ; Simon Tanguay [Canada] ; Stephen Lee [Canada] ; Lakshman Gunaratnam [Canada] ; Nathalie Arbour [Canada] ; Réjean Lapointe [Canada]Source :
- Cancer Immunology, Immunotherapy [ 0340-7004 ] ; 2009-08-01.
English descriptors
- KwdEn :
Abstract
Abstract: Objectives: Patients with renal cell carcinomas (RCC) have few treatment options, underscoring the importance of developing new approaches such as immunotherapy. However, few tumor associated antigens (TAA), which can be targeted by immunotherapy, have been identified for this type of cancer. von Hippel-Lindau clear cell RCC (VHL−/−RCC) are characterized by mutations in the VHL tumor suppressor gene. Loss of VHL function causes the overexpression of transforming growth factor (TGF)-α, leading us to hypothesize that TGF-α could be a potential TAA for immunotherapy of kidney cancer, which was evaluated in this study. Methods and results: We first confirmed the absent or weak expression of TGF-α in important normal tissues as well as its overexpression in 61% of renal tumors in comparison to autologous normal kidney tissues. In addition, we demonstrated the immunogenicity of TGF-α, by expanding many T cell lines specific for certain TGF-α peptides or the mature TGF-α protein, when presented by major histocompatibility complex (MHC) molecules on the surface of antigen-presenting cells. Interestingly, some of these TGF-α-specific T cells were polyfunctionals and secreted IFN-γ, TNF-α and IL-2. Conclusion: We have shown that TGF-α is a valid candidate TAA, which should allow the development of a targeted immunotherapy.
Url:
DOI: 10.1007/s00262-008-0630-2
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000A53
- to stream Istex, to step Curation: 000A53
- to stream Istex, to step Checkpoint: 000766
- to stream Main, to step Merge: 002A78
- to stream Main, to step Curation: 002A52
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">TGF-alpha as a candidate tumor antigen for renal cell carcinomas</title><author><name sortKey="Pelletier, Sandy" sort="Pelletier, Sandy" uniqKey="Pelletier S" first="Sandy" last="Pelletier">Sandy Pelletier</name></author><author><name sortKey="Tanguay, Simon" sort="Tanguay, Simon" uniqKey="Tanguay S" first="Simon" last="Tanguay">Simon Tanguay</name></author><author><name sortKey="Lee, Stephen" sort="Lee, Stephen" uniqKey="Lee S" first="Stephen" last="Lee">Stephen Lee</name></author><author><name sortKey="Gunaratnam, Lakshman" sort="Gunaratnam, Lakshman" uniqKey="Gunaratnam L" first="Lakshman" last="Gunaratnam">Lakshman Gunaratnam</name></author><author><name sortKey="Arbour, Nathalie" sort="Arbour, Nathalie" uniqKey="Arbour N" first="Nathalie" last="Arbour">Nathalie Arbour</name></author><author><name sortKey="Lapointe, Rejean" sort="Lapointe, Rejean" uniqKey="Lapointe R" first="Réjean" last="Lapointe">Réjean Lapointe</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3A1B1D84FBCA34575A0115000590EF8E14FB5086</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1007/s00262-008-0630-2</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-VB423FRW-N/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000A53</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000A53</idno><idno type="wicri:Area/Istex/Curation">000A53</idno><idno type="wicri:Area/Istex/Checkpoint">000766</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000766</idno><idno type="wicri:doubleKey">0340-7004:2008:Pelletier S:tgf:alpha:as</idno><idno type="wicri:Area/Main/Merge">002A78</idno><idno type="wicri:Area/Main/Curation">002A52</idno><idno type="wicri:Area/Main/Exploration">002A52</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">TGF-alpha as a candidate tumor antigen for renal cell carcinomas</title><author><name sortKey="Pelletier, Sandy" sort="Pelletier, Sandy" uniqKey="Pelletier S" first="Sandy" last="Pelletier">Sandy Pelletier</name><affiliation wicri:level="3"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, CRCHUM-Hôpital Notre-Dame, Université de Montréal, Montreal</wicri:regionArea><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Institut du Cancer de Montreal, Montreal, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author><author><name sortKey="Tanguay, Simon" sort="Tanguay, Simon" uniqKey="Tanguay S" first="Simon" last="Tanguay">Simon Tanguay</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>McGill University Health Centre, Montreal General Hospital, Montreal, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author><author><name sortKey="Lee, Stephen" sort="Lee, Stephen" uniqKey="Lee S" first="Stephen" last="Lee">Stephen Lee</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Gunaratnam, Lakshman" sort="Gunaratnam, Lakshman" uniqKey="Gunaratnam L" first="Lakshman" last="Gunaratnam">Lakshman Gunaratnam</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Arbour, Nathalie" sort="Arbour, Nathalie" uniqKey="Arbour N" first="Nathalie" last="Arbour">Nathalie Arbour</name><affiliation wicri:level="3"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, CRCHUM-Hôpital Notre-Dame, Université de Montréal, Montreal</wicri:regionArea><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Lapointe, Rejean" sort="Lapointe, Rejean" uniqKey="Lapointe R" first="Réjean" last="Lapointe">Réjean Lapointe</name><affiliation wicri:level="3"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, CRCHUM-Hôpital Notre-Dame, Université de Montréal, Montreal</wicri:regionArea><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Institut du Cancer de Montreal, Montreal, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de Recherche, CRCHUM-Hôpital Notre-Dame, Pavillon De Sève, Y-5605, 2099 rue Alexandre De Sève, H2L 4M1, Montreal, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Canada</country></affiliation></author></analytic><monogr></monogr><series><title level="j">Cancer Immunology, Immunotherapy</title><title level="j" type="abbrev">Cancer Immunol Immunother</title><idno type="ISSN">0340-7004</idno><idno type="eISSN">1432-0851</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="2009-08-01">2009-08-01</date><biblScope unit="volume">58</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1207">1207</biblScope><biblScope unit="page" to="1218">1218</biblScope></imprint><idno type="ISSN">0340-7004</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0340-7004</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cancer immunotherapy</term><term>Clear cell renal cell carcinoma</term><term>Polyfunctional antigen-specific T lymphocytes</term><term>Transforming growth factor (TGF)-α</term><term>Tumor antigen</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Objectives: Patients with renal cell carcinomas (RCC) have few treatment options, underscoring the importance of developing new approaches such as immunotherapy. However, few tumor associated antigens (TAA), which can be targeted by immunotherapy, have been identified for this type of cancer. von Hippel-Lindau clear cell RCC (VHL−/−RCC) are characterized by mutations in the VHL tumor suppressor gene. Loss of VHL function causes the overexpression of transforming growth factor (TGF)-α, leading us to hypothesize that TGF-α could be a potential TAA for immunotherapy of kidney cancer, which was evaluated in this study. Methods and results: We first confirmed the absent or weak expression of TGF-α in important normal tissues as well as its overexpression in 61% of renal tumors in comparison to autologous normal kidney tissues. In addition, we demonstrated the immunogenicity of TGF-α, by expanding many T cell lines specific for certain TGF-α peptides or the mature TGF-α protein, when presented by major histocompatibility complex (MHC) molecules on the surface of antigen-presenting cells. Interestingly, some of these TGF-α-specific T cells were polyfunctionals and secreted IFN-γ, TNF-α and IL-2. Conclusion: We have shown that TGF-α is a valid candidate TAA, which should allow the development of a targeted immunotherapy.</div></front></TEI><affiliations><list><country><li>Canada</li></country><region><li>Québec</li></region><settlement><li>Montréal</li></settlement></list><tree><country name="Canada"><region name="Québec"><name sortKey="Pelletier, Sandy" sort="Pelletier, Sandy" uniqKey="Pelletier S" first="Sandy" last="Pelletier">Sandy Pelletier</name></region><name sortKey="Arbour, Nathalie" sort="Arbour, Nathalie" uniqKey="Arbour N" first="Nathalie" last="Arbour">Nathalie Arbour</name><name sortKey="Gunaratnam, Lakshman" sort="Gunaratnam, Lakshman" uniqKey="Gunaratnam L" first="Lakshman" last="Gunaratnam">Lakshman Gunaratnam</name><name sortKey="Lapointe, Rejean" sort="Lapointe, Rejean" uniqKey="Lapointe R" first="Réjean" last="Lapointe">Réjean Lapointe</name><name sortKey="Lapointe, Rejean" sort="Lapointe, Rejean" uniqKey="Lapointe R" first="Réjean" last="Lapointe">Réjean Lapointe</name><name sortKey="Lapointe, Rejean" sort="Lapointe, Rejean" uniqKey="Lapointe R" first="Réjean" last="Lapointe">Réjean Lapointe</name><name sortKey="Lapointe, Rejean" sort="Lapointe, Rejean" uniqKey="Lapointe R" first="Réjean" last="Lapointe">Réjean Lapointe</name><name sortKey="Lee, Stephen" sort="Lee, Stephen" uniqKey="Lee S" first="Stephen" last="Lee">Stephen Lee</name><name sortKey="Pelletier, Sandy" sort="Pelletier, Sandy" uniqKey="Pelletier S" first="Sandy" last="Pelletier">Sandy Pelletier</name><name sortKey="Tanguay, Simon" sort="Tanguay, Simon" uniqKey="Tanguay S" first="Simon" last="Tanguay">Simon Tanguay</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A52 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002A52 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:3A1B1D84FBCA34575A0115000590EF8E14FB5086
|texte= TGF-alpha as a candidate tumor antigen for renal cell carcinomas
}}
| This area was generated with Dilib version V0.6.33. |  |